middle.news
Cynata Therapeutics Poised for Key Trial Results, Extends Cash Runway to Mid-2026
9:42am on Thursday 29th of January, 2026 AEDT
•
Biotechnology
Read Story
Cynata Therapeutics Poised for Key Trial Results, Extends Cash Runway to Mid-2026
9:42am on Thursday 29th of January, 2026 AEDT
Key Points
Phase 3 osteoarthritis trial final patient visits completed; results due Q2 2026
Phase 2 acute graft versus host disease trial enrolment completed; results expected June 2026
Positive safety review in Phase 1/2 kidney transplant trial; second cohort underway
Cash balance of ~$2.6 million at quarter end, with $1.2 million raised post-quarter
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CYNATA THERAPEUTICS (ASX:CYP)
OPEN ARTICLE